復星醫藥(02196.HK)建議收購PHIXEN S.A.S.全部股權
格隆匯11月30日丨復星醫藥(02196.HK)發佈公吿，2022年11月29日，買方和買方控股公司(皆為公司的附屬公司)與賣方(包括中法(併購)基金、Kaphy Invest、FCPE和Manxen賣方)簽訂出售選擇權協議，據此，買方不可撤銷地授出出售選擇權，承諾於中法(併購)基金(為其自身及作為其他賣方的代理人)行使該出售選擇權後，買方將簽訂股權購買協議，購買賣方持有的目標公司(即Phixen société par actions simplifiée)的直接╱間接股權，並向目標集團提供股東借款。買方根據出售選擇權協議承諾的轉讓對價及股東借款總額不超過約2.104億歐元。建議收購交割後，買方將直接及間接持有目標公司全部股權，目標集團以及Manxen公司將成為公司的附屬公司。
目標集團於2004年於法國成立，其現任總裁及首席執行官為Christophe Durand先生。目標集團專注於CDMO(即合同研發生產組織)業務，在無菌產品(包括高壁壘複雜製劑)、生物製品的技術開發和製造領域擁有豐富的技術積累和經驗。目標集團擁有全球化、多樣化的客户基礎，已累計服務客户超過100家(以大型跨國製藥企業和中型歐洲製藥企業為主)。截至該公吿日，目標公司及7家全資附屬公司所轄的4個生產基地(其中3個位於法國、1個位於比利時)均已通過美國食品藥品監督管理局認證、歐洲藥品管理局認證、巴西衞生監管局認證。
公吿表示，目標集團專注於CDMO業務，在無菌產品(包括高壁壘複雜製劑)、生物製品的技術開發和製造領域擁有豐富的技術積累和經驗。目標集團擁有全球化、多樣化的客户基礎，已累計服務客户超過100家(以大型跨國製藥企業和中型歐洲製藥企業為主)。目標集團的CDMO業務模式與Gland Pharma集團的長期發展規劃相契合。建議收購交割後，通過獲得歐洲本地生產基地，Gland Pharma集團將實現歐洲市場產品和服務供應能力的拓展；同時有利於提升Gland Pharma集團複雜製劑和生物製品的開發、製造及供應能力，和豐富客户資源。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
